公开(公告)号：US20240101608A1

公开(公告)日：2024-03-28

申请号：US18528065

申请日：2023-12-04

Applicant: CureVac SE

Inventor： Patrick BAUMHOF ,  Susanne RAUCH ,  Aleksandra KOWALCZYK ,  Johannes LUTZ ,  Edith JASNY ,  Benjamin PETSCH ,  Andreas THESS ,  Thomas SCHLAKE ,  Mariola FOTIN-MLECZEK ,  Regina HEIDENREICH ,  Sandra LAZZARO ,  Fatma FUNKNER ,  Wolfgang GROSSE

IPC: C07K14/005 ,  A61K39/12 ,  A61K39/145 ,  A61P31/16 ,  C07K14/205 ,  C12N15/00

CPC classification number: C07K14/005 ,  A61K39/12 ,  A61K39/145 ,  A61P31/16 ,  C07K14/205 ,  C12N15/00 ,  A61K2039/53

Abstract: The present invention provides optimized nucleic acid molecules, methods for optimization of nucleic acid molecules and uses of optimized nucleic acid molecules. A modular design principle is provided that is suitable to generate a nucleic acid, particularly mRNA, which is tailored for a respective application. The nucleic acid molecules of the present invention can be obtained by the versatile combination of multiple modules on nucleic acid level. Such nucleic acid, e.g. mRNA, can be tailored by combining one or more modules, comprising (i) a nucleic acid moiety encoding a polypeptide of interest (e.g. a protein potentially producing a therapeutic outcome) and (ii) at least one further coding or non-coding nucleic acid moiety, e.g. selected among nucleic acid moieties encoding a polypeptide element, such as a secretory signal peptide (SSP), a multimerization element (dimerization, trimerization, tetramerization and oligomerization), a virus like particle (VLP) forming element, a transmembrane element, a dendritic cell targeting element, an immunological adjuvant element, an element promoting antigen presentation; a 2A peptide; a peptide linker element, elements that extend protein half-life, and/or any other polypeptide or protein. Non-coding nucleic acid moieties may be selected e.g. from the group comprising 3′-UTR, 5′-UTR, IRES element, miRNA moiety, histone stem loop, poly(C) sequence, polyadenylation signal, polyA-sequence. The optimized nucleic acid molecule can further be characterized by the presence of at least one modified nucleoside. The versatility of the present invention allows for rational design of a large variety of different nucleic acid molecules with desired properties.

公开(公告)号：US20230227881A1

公开(公告)日：2023-07-20

申请号：US18154437

申请日：2023-01-13

Applicant: CureVac SE

Inventor： Tilmann ROOS ,  Benyamin YAZDAN PANAH ,  Markus CONZELMANN ,  Andreas THESS ,  Dominik BUOB ,  Martin KUNZE ,  Veronika WAGNER

IPC: C12P19/34 ,  C12N9/10 ,  C12N9/16 ,  C12N9/12 ,  C12N11/02 ,  C12N11/087 ,  C12N11/098

CPC classification number: C12P19/34 ,  C12N9/1007 ,  C12Y201/01057 ,  C12Y201/01056 ,  C12Y301/03033 ,  C12N9/16 ,  C12Y207/0705 ,  C12N9/1241 ,  C12N11/02 ,  C12N11/087 ,  C12N11/098

Abstract: The present invention relates to an immobilized capping enzyme, preferably an immobilized Vaccinia virus capping enzyme. Furthermore, the present invention relates to an immobilized cap-specific nucleoside 2′-O-methyltransferase, preferably an immobilized Vaccinia virus cap-specific nucleoside 2′-O-methyltransferase. Moreover, the present invention relates to a method for immobilizing said enzymes and to a method of using said enzymes for the addition of a 5′-cap structure to RNAs. Moreover, the present invention relates to an enzyme reactor for performing the capping reaction using said immobilized enzymes and the subsequent separation of the 5′-capped RNA product. In addition, the present invention relates to a kit comprising the capping enzyme and/or the cap-specific nucleoside 2′-O-methyltransferase.

公开(公告)号：US20230313207A1

公开(公告)日：2023-10-05

申请号：US18330356

申请日：2023-06-06

Applicant: CureVac SE

Inventor： Andreas THESS ,  Thomas SCHLAKE ,  Stefanie GRUND

IPC: C12N15/67 ,  A61K39/12 ,  C12N15/85 ,  A61K39/145 ,  A61K39/205 ,  C12N15/68

CPC classification number: C12N15/67 ,  A61K39/12 ,  C12N15/85 ,  A61K39/145 ,  A61K39/205 ,  C12N15/68 ,  A61K48/00

Abstract: The invention relates to an artificial nucleic acid molecule comprising an open reading frame and a 3′-UTR comprising at least one poly(A) sequence or a polyadenylation signal. The invention further relates to a vector comprising the artificial nucleic acid molecule comprising an open reading frame and a 3′-UTR comprising at least one poly(A) sequence or a polyadenylation signal, to a cell comprising the artificial nucleic acid molecule or the vector, to a pharmaceutical composition comprising the artificial nucleic acid molecule or the vector and to a kit comprising the artificial nucleic acid molecule, the vector and/or the pharmaceutical composition. The invention also relates to a method for increasing protein production from an artificial nucleic acid molecule and to the use of a 3′-UTR for a method for increasing protein production from an artificial nucleic acid molecule. Moreover, the invention concerns the use of the artificial nucleic acid molecule, the vector, the kit or the pharmaceutical composition as a medicament, as a vaccine or in gene therapy.

公开(公告)号：US20250152745A1

公开(公告)日：2025-05-15

申请号：US18824886

申请日：2024-09-04

Applicant: CureVac SE

Inventor： Andreas THESS ,  Thomas SCHLAKE ,  Jochen PROBST

IPC: A61K48/00 ,  A61K39/00 ,  C07K14/435 ,  C12N15/67

Abstract: The present application describes a coding nucleic acid sequence, particularly a messenger RNA (mRNA), comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal and the use thereof for increasing the expression of an encoded protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine e.g. for the use in the treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases or genetic diseases, or in gene therapy. The present invention further describes an in vitro transcription method, in vitro methods for increasing the expression of a protein using the nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal and an ex vivo and in vivo method.